Literature DB >> 33765256

High numbers of programmed cell death-1-positive tumor infiltrating lymphocytes correlate with early onset of post-transplant lymphoproliferative disorder.

Hideaki Saito1, Hiroaki Miyoshi2, Hirohiko Shibayama3, Jun Toda1, Shinsuke Kusakabe1, Michiko Ichii1, Jiro Fujita1, Kentaro Fukushima1, Tetsuo Maeda1,4, Masao Mizuki1, Kenji Oritani5, Masao Seto2, Takafumi Yokota1, Yuzuru Kanakura1,6, Naoki Hosen1, Koichi Ohshima2.   

Abstract

Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication of transplantation. In addition to reactivation of Epstein-Barr virus in immunocompromised patients, impaired tumor immunity is suggested to be a risk factor for PTLD. However, it remains unclear whether immune suppressive tumor-infiltrating lymphocytes (TILs) correlate with the occurrence or prognosis of PTLD. We analyzed TILs in 26 patients with PTLD to elucidate the clinicopathological significance of the expression of PD-1 and FoxP3, which are associated with exhausted T-cells and regulatory T-cells (Tregs), respectively. Numbers of PD-1+ TILs in the PTLD specimens were significantly higher in patients who developed PTLD early after transplantation (P = 0.0040), while numbers of FoxP3+ TILs were not (P = 0.184). There was no difference in overall response rate regardless of the expression of PD-1 or FoxP3. FoxP3high patients tended to have a shorter time to progression compared with FoxP3low patients, especially in the case of FoxP3high patients with diffuse large B-cell lymphoma-subtype PTLD (P = 0.011), while PD-1high patients did not. These results suggest that T-cell exhaustion may be mainly associated with PTLD development, while immune suppression by Tregs may be dominant in enhanced progression of PTLD following disease occurrence.

Entities:  

Keywords:  FoxP3; PD-1; PTLD; Tumor-infiltrating lymphocytes

Year:  2021        PMID: 33765256     DOI: 10.1007/s12185-021-03129-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  47 in total

1.  Cancers complicating organ transplantation.

Authors:  I Penn
Journal:  N Engl J Med       Date:  1990-12-20       Impact factor: 91.245

Review 2.  Post-Transplantation Lymphoproliferative Disorders in Adults.

Authors:  Daan Dierickx; Thomas M Habermann
Journal:  N Engl J Med       Date:  2018-02-08       Impact factor: 91.245

3.  Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases?

Authors:  Irene M Ghobrial; Thomas M Habermann; William R Macon; Kay M Ristow; Timothy S Larson; Randall C Walker; Stephen M Ansell; Gregory J Gores; Mark D Stegall; Christopher G McGregor
Journal:  Transplantation       Date:  2005-01-27       Impact factor: 4.939

4.  EBV-Positive and EBV-Negative Posttransplant Diffuse Large B Cell Lymphomas Have Distinct Genomic and Transcriptomic Features.

Authors:  J Finalet Ferreiro; J Morscio; D Dierickx; P Vandenberghe; O Gheysens; G Verhoef; M Zamani; T Tousseyn; I Wlodarska
Journal:  Am J Transplant       Date:  2016-01-18       Impact factor: 8.086

Review 5.  The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.

Authors:  Olivia M Martinez; Sheri M Krams
Journal:  Transplantation       Date:  2017-09       Impact factor: 4.939

6.  Lymphomas after solid organ transplantation: a collaborative transplant study report.

Authors:  Gerhard Opelz; Bernd Döhler
Journal:  Am J Transplant       Date:  2004-02       Impact factor: 8.086

7.  Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors.

Authors:  Daan Dierickx; Thomas Tousseyn; Xavier Sagaert; Steffen Fieuws; Iwona Wlodarska; Julie Morscio; Lieselot Brepoels; Dirk Kuypers; Johan Vanhaecke; Frederik Nevens; Geert Verleden; Rita Van Damme-Lombaerts; Marleen Renard; Jacques Pirenne; Christiane De Wolf-Peeters; Gregor Verhoef
Journal:  Leuk Lymphoma       Date:  2013-04-09

8.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Authors:  Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

Review 9.  Oncology meets immunology: the cancer-immunity cycle.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

Review 10.  Microenvironment Cell Contribution to Lymphoma Immunity.

Authors:  Deepika Kumar; Mina L Xu
Journal:  Front Oncol       Date:  2018-07-27       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.